Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

Alternative markers such as CD229 and CD319 can also be introduced into a panel, meaning that it is advisable to check whether or not a targeted antigen is expressed on the malignant plasma cells ...

Dr Matthew McKinney reflects on his first experience of treating DLBCL and highlights the advancements in emerging treatments ...

Unable to be estimated due to no events among patients with pre-existing autoimmune or inflammatory disease. A previous study 3 used commercially aggregated electronic health record data and diagnosis ...

Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease Indications; Inno ...

Cell therapy is a field ... vastly improving the patient experience. “The primary goal of chemotherapy for autologous cell therapies is to eliminate the circulating T-cells inside the body ...

Like other CAR-Ts, Calibr's therapy is manufactured from a patient's own T-cells, which are harvested and genetically modified to fight cancer before being reintroduced into the body. However ...